VADS DEBIO 1143-202 Pre-operative window-of-opportunity study of Debio 1143 with or without cisplatin in patients with resectable squamous cell carcinoma of the head and neck. Paris CHRISTOPHE LE TOURNEAU
Recherches "plusieurs pathologies" CUPISCO (MX39795) A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY. Paris CHRISTOPHE LE TOURNEAU
Appareil pulmonaire AMG20200491 - DeLLPhi-301 A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment. Paris PAULINE DU RUSQUEC
Appareil pulmonaire FRACTION-LUNG (CA018-001) A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung) Paris EMANUELA ROMANO
Appareil pulmonaire SAFIR 02 Lung Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer (Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung) Paris CATHERINE DANIEL
Sein Métastatique SAFIR02 Breast Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer. Paris, Saint-Cloud MARIE PAULE SABLIN
Recherches "plusieurs pathologies" AcSé Nivolumab Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Paris
Appareil pulmonaire ATALK - ML39349 An Open-Label, Multicenter, Single-Arm, Phase II Study to Assess the Efficacy and Safety of Alectinib in Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on Prior ALK Inhibitor Therapy Paris NICOLAS GIRARD
Sein métastatique HER2+ HER2CLIMB (ONT-380-206) Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) Paris
VADS TOPNIVO - ORL09 A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN). Paris CHRISTOPHE LE TOURNEAU